{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:29:29Z","timestamp":1789187369266,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302061"],"award-info":[{"award-number":["82302061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126959","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T19:05:51Z","timestamp":1740855951000},"page":"126959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector"],"prefix":"10.1016","volume":"53","author":[{"given":"Yixin","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126959_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"Krammer","year":"2018","journal-title":"Influenza Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2025.126959_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222381","article-title":"The epidemiological signature of influenza B virus and its B\/Victoria and B\/Yamagata lineages in the 21st century","volume":"14","author":"Caini","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126959_bb0015","series-title":"Recommendations announced for influenza vaccine composition for the 2023-2024 Northern hemisphere influenza season","year":"2025"},{"key":"10.1016\/j.vaccine.2025.126959_bb0020","first-page":"2024","author":"Chen Fang","year":"2024","journal-title":"FDA VRBPAC Influenza Strain Recommendations"},{"key":"10.1016\/j.vaccine.2025.126959_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-020-0206-5","article-title":"Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection","volume":"5","author":"Wang","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126959_bb0030","first-page":"13","article-title":"Targeting antigens for universal influenza vaccine development","author":"Nguyen","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.126959_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038778","article-title":"Influenza hemagglutinin structures and antibody recognition","volume":"10","author":"Wu","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2025.126959_bb0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2025.126959_bb0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s12257-022-0115-8","article-title":"Influenza vaccine: an engineering vision from Virological importance to production","volume":"27","author":"Demirden","year":"2022","journal-title":"Biotechnol Bioprocess Eng"},{"key":"10.1016\/j.vaccine.2025.126959_bb0050","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiz003","article-title":"The role of matrix protein 2 Ectodomain in the development of universal influenza vaccines","volume":"219","author":"Saelens","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126959_bb0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-019-0572-3","article-title":"M2e-based universal influenza vaccines: a historical overview and new approaches to development","volume":"26","author":"Mezhenskaya","year":"2019","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2025.126959_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4110\/in.2015.15.5.213","article-title":"Mechanisms of cross-protection by influenza virus M2-based vaccines","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2025.126959_bb0065","first-page":"9","article-title":"M2e-based influenza vaccines with nucleoprotein: a review","author":"Tan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126959_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124677","article-title":"A human anti-M2 antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and cytokine secretion by resting and cytokine-Preactivated natural killer (NK) cells","volume":"10","author":"Simhadri","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126959_bb0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3201\/eid1303.061125","article-title":"Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1","volume":"13","author":"Tompkins","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126959_bb0080","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2004.02.021","article-title":"Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys","volume":"22","author":"Fan","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126959_bb0085","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2008.04.052","article-title":"Development of a universal influenza a vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform","volume":"26","author":"Denis","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126959_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2016.06.045","article-title":"Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses","volume":"237","author":"Fernando","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2025.126959_bb0095","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1099\/vir.0.029777-0","article-title":"Endogenously expressed matrix protein M1 and nucleoprotein of influenza a are efficiently presented by class I and class II major histocompatibility complexes","volume":"92","author":"Doucet","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0100","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1016\/j.vaccine.2019.07.033","article-title":"Highly conserved influenza T cell epitopes induce broadly protective immunity","volume":"37","author":"Eickhoff","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126959_bb0105","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.micinf.2008.07.002","article-title":"Heterosubtypic immunity to influenza a virus: where do we stand?","volume":"10","author":"Grebe","year":"2008","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.126959_bb0110","article-title":"Rapid, Efficient, and modular generation of adenoviral vectors via isothermal assembly","volume":"113","author":"Yang","year":"2016","journal-title":"Curr Protoc Mol Biol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0115","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/nprot.2014.180","article-title":"Influenza a virus isolation, culture and identification","volume":"9","author":"Eisfeld","year":"2014","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2025.126959_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101151","article-title":"Protocol for influenza a virus infection of mice and viral load determination","volume":"3","author":"Galani","year":"2022","journal-title":"STAR Protoc"},{"key":"10.1016\/j.vaccine.2025.126959_bb0125","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(86)90019-X","article-title":"The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides","volume":"44","author":"Townsend","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126959_bb0130","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbrc.2018.05.148","article-title":"Identification of immunodominant CD8 epitope in the stalk domain of influenza B viral hemagglutinin","volume":"502","author":"Muralidharan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2025.126959_bb0135","doi-asserted-by":"crossref","first-page":"7841","DOI":"10.1128\/JVI.00976-15","article-title":"Repeated low-dose influenza virus infection causes severe disease in mice: a model for vaccine evaluation","volume":"89","author":"Song","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0140","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1128\/JVI.02667-05","article-title":"Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity","volume":"80","author":"Krause","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0145","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2025.126959_bb0150","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1073\/pnas.0401279101","article-title":"Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope","volume":"101","author":"Kedzierska","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.126959_bb0155","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1073\/pnas.101132698","article-title":"Measuring the diaspora for virus-specific CD8+ T cells","volume":"98","author":"Marshall","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.126959_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00408-20","article-title":"Potential role of nonneutralizing IgA antibodies in cross-protective immunity against influenza a viruses of multiple hemagglutinin subtypes","volume":"94","author":"Okuya","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0165","first-page":"11","article-title":"Novel influenza vaccines: from Research and Development (R&D) challenges to regulatory responses","author":"He","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126959_bb0170","first-page":"8","article-title":"Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines","author":"Sayedahmed","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126959_bb0175","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41577-024-01030-8","article-title":"Opportunities and challenges for T cell-based influenza vaccines","volume":"24","author":"Mosmann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136996","article-title":"Antiviral drug development by targeting RNA binding site, oligomerization and nuclear export of influenza nucleoprotein","volume":"282","author":"Panthi","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0185","first-page":"818","article-title":"Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza a viruses that are directed toward the nucleoprotein","volume":"215","author":"Jegaskanda","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126959_bb0190","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","article-title":"A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus","volume":"181","author":"Carragher","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0195","doi-asserted-by":"crossref","first-page":"13706","DOI":"10.1128\/JVI.01666-13","article-title":"Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques","volume":"87","author":"Jegaskanda","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.126959_bb0200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/infdis\/148.5.785","article-title":"Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells","volume":"148","author":"Hashimoto","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126959_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011670","article-title":"Protective mechanisms of nonneutralizing antiviral antibodies","volume":"19","author":"Chandler","year":"2023","journal-title":"PLoS Pathog"},{"issue":"169\u201384","key":"10.1016\/j.vaccine.2025.126959_bb0210","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126959_bb0215","first-page":"13","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126959_bb0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126959_bb0225","first-page":"147","article-title":"Antibody response and protection after receipt of inactivated influenza vaccine: a systematic review","author":"Wall","year":"2021","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:25:26Z","timestamp":1745130326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"alternative-id":["S0264410X25002567"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126959","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126959"}}